Buy now

  

|

Buy now

Clinical outcomes insulin requiring diabetes

Clinical outcomes insulin requiring diabetes

FreeStyle Libre has been clinically shown to help reduce HbA1c in people living with T1D and Insulin-requiring T2D

Type 1 diabetes

A1c inside a circle next to a blue downwards arrow showing a decrease of 0.53 percent.

After 12-16 weeks

In adults with T1D using FreeStyle Libre (p<0.0001 vs. baseline)4

Type 2 diabetes

A1c inside a circle next to a wide blue downwards arrow showing a decrease of 0.82 percent.

After 10 weeks

In people with T2D on multiple daily injections of insulin and FreeStyle Libre (p=0.005 vs. standard blood glucose monitoring)3

A1c inside a circle next to a wide blue downwards arrow showing a decrease of 1.1 percent.

After 22 weeks

In people with T2D who were using basal insulin and FreeStyle Libre (p<0.001 vs. baseline A1c)13

FreeStyle Libre has been proven to increase Time in Range by 43%14

time in range cgm

More frequent scanning of the FreeStyle Libre sensor has been proven to increase Time in Range14

FreeStyle Libre has been shown to help reduce low glucose events in insulin-using people with both T1D and T2D5,6

Type 1 diabetes

Type 1 diabetes

After 6 months

less time spent in hypo in people with T1D

(p=0.0001 vs. standard blood glucose monitoring)5

A 6-month RCT in 328 well-controlled T1D patients (with baseline A1c ≤7.5%) proves the FreeStyle Libre system safely and successfully replaces SMBG5

Type 2 diabetes

Type 2 diabetes

After 6 months

less time spent in hypo in people with T2D

(p=0.0006 vs. standard blood glucose monitoring)6

A 6-month RCT in 224 T2D patients on intensive insulin therapy proves the FreeStyle Libre system safely and successfully replaces SMBG6

A reduction in hypoglycemic episodes could help you enjoy a better quality of life15

Use of the FreeStyle Libre system is associated with significant reduction in diabetes-related complications9,15

Type 1 diabetes

Type 1 diabetes

decrease in hospital admissions of diabetic ketoacidosis (DKA) or hypoglycaemic events from 3.3% to 2.2% at 12 months15

(p=0.0031)

Use of the FreeStyle Libre system is associated with a 66% decrease in diabetes-related hospital admissions.9,15

Disclaimer - Images are for illustration purpose only. No actual patient data. Any person depicted in the photos is a model

Abbreviations: HbA1c: glycated haemoglobin; hypo: hypoglycaemic event; RCT: randomised controlled trial; SMBG: self-monitoring of blood glucose; T1D: type 1 diabetes; T2D: type 2 diabetes.

Cookie Policy and Disclaimer

FreeStyle Libre uses cookies to give you the best website experience. By using our website, you consent to the use of cookies per our privacy policy. FreeStyle.abbott/in-en is a product specific website only intended for residents of India.

Change country
India (en-IN)

The FreeStyle Libre continuous glucose monitoring system is indicated for measuring interstitial fluid glucose levels in people (age 4 and older) with diabetes mellitus. The indication for children (age 4 – 17) is limited to those who are supervised by a caregiver at least 18 years old who is responsible for supervising, managing, and assisting the child in using the FreeStyle Libre system and interpreting its readings.

Health care professionals and consumers should be aware about the limitations of available scientific evidence for use of this device in any other groups of patients who require diabetes management. Always read the label and use as directed.

For more information call Customer Service on 1800 2100 998

No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of AHPL, except to identify the product or services of the company. The product images are for illustrative purposes only.

Disclaimer
www.FreeStyleLibre.co.in is a product-specific website intended only for residents of India. If you are resident of another country, please contact your local Abbott affiliate to obtain the appropriate product information for your country of residence.

Abbott Logo

© 2023 Abbott. All rights reserved. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. ADC-82306 v2.0 11/23

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.

The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?